Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

71 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program.
González-Cao M, Arance A, Piulats JM, Marquez-Rodas I, Manzano JL, Berrocal A, Crespo G, Rodriguez D, Perez-Ruiz E, Berciano M, Soria A, Castano AG, Espinosa E, Montagut C, Alonso L, Puertolas T, Aguado C, Royo MA, Blanco R, Rodríguez JF, Muñoz E, Mut P, Barron F, Martin-Algarra S; Spanish Melanoma Group. González-Cao M, et al. Among authors: barron f. Clin Transl Oncol. 2017 Jun;19(6):761-768. doi: 10.1007/s12094-016-1602-1. Epub 2017 Jan 4. Clin Transl Oncol. 2017. PMID: 28054320
Fatal gastrointestinal toxicity with ipilimumab after BRAF/MEK inhibitor combination in a melanoma patient achieving pathological complete response.
Gonzalez-Cao M, Boada A, Teixidó C, Fernandez-Figueras MT, Mayo C, Tresserra F, Bustamante J, Viteri S, Puertas E, Santarpia M, Riso A, Barron F, Karachaliou N, Rosell R. Gonzalez-Cao M, et al. Among authors: barron f. Oncotarget. 2016 Aug 30;7(35):56619-56627. doi: 10.18632/oncotarget.10651. Oncotarget. 2016. PMID: 27447748 Free PMC article.
Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP).
Ruiz-Patiño A, Arrieta O, Cardona AF, Martín C, Raez LE, Zatarain-Barrón ZL, Barrón F, Ricaurte L, Bravo-Garzón MA, Mas L, Corrales L, Rojas L, Lupinacci L, Perazzo F, Bas C, Carranza O, Puparelli C, Rizzo M, Ruiz R, Rolfo C, Archila P, Rodríguez J, Sotelo C, Vargas C, Carranza H, Otero J, Pino LE, Ortíz C, Laguado P, Rosell R; CLICaP. Ruiz-Patiño A, et al. Among authors: barron f. Thorac Cancer. 2020 Feb;11(2):353-361. doi: 10.1111/1759-7714.13272. Epub 2019 Dec 12. Thorac Cancer. 2020. PMID: 31828967 Free PMC article.
Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
Arrieta O, Barrón F, Ramírez-Tirado LA, Zatarain-Barrón ZL, Cardona AF, Díaz-García D, Yamamoto Ramos M, Mota-Vega B, Carmona A, Peralta Álvarez MP, Bautista Y, Aldaco F, Gerson R, Rolfo C, Rosell R. Arrieta O, et al. Among authors: barron f. JAMA Oncol. 2020 Jun 1;6(6):856-864. doi: 10.1001/jamaoncol.2020.0409. JAMA Oncol. 2020. PMID: 32271354 Free PMC article. Clinical Trial.
Characteristics and outcomes of thymomas in Latin America: Results from over 10 years of experience (CLICaP-LATimus).
Martín C, Enrico D, Mas L, Patane AK, Arrieta O, Soria T, Cardona AF, Ruiz-Patiño A, Ruiz R, Rioja P, Lozano S, Zatarain-Barrón ZL, Barrón F, Puparelli C, Tsou F, Corassa MP, Freitas HC, Cordeiro de Lima VC, Rojas L, Ordóñez-Reyes C, Corrales L, Sotelo C, Rodríguez J, Ricaurte L, Ávila J, Archila P, Rosell R, Cuello M, Remon J; CLICaP. Martín C, et al. Among authors: barron f. Thorac Cancer. 2021 May;12(9):1328-1335. doi: 10.1111/1759-7714.13901. Epub 2021 Mar 17. Thorac Cancer. 2021. PMID: 33729676 Free PMC article.
Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non-small cell lung cancer (AB-CLICaP).
Ruiz-Patiño A, Barrón F, Cardona AF, Corrales L, Mas L, Martín C, Zatarain-Barrón ZL, Recondo G, Ricaurte L, Rojas L, Archila P, Rodríguez J, Sotelo C, Viola L, Vargas C, Carranza H, Otero J, Pino LE, Rolfo C, Rosell R, Arrieta O; CLICaP. Ruiz-Patiño A, et al. Among authors: barron f. Thorac Cancer. 2020 Sep;11(9):2552-2560. doi: 10.1111/1759-7714.13573. Epub 2020 Jul 24. Thorac Cancer. 2020. PMID: 32705787 Free PMC article.
p.G12C KRAS mutation prevalence in non-small cell lung cancer: Contribution from interregional variability and population substructures among Hispanics.
Ruiz-Patiño A, Rodríguez J, Cardona AF, Ávila J, Archila P, Carranza H, Vargas C, Otero J, Arrieta O, Zatarain-Barrón L, Sotelo C, Ordoñez C, García-Robledo JE, Rojas L, Bermúdez M, Gámez T, Mayorga D, Corrales L, Martín C, Recondo G, Mas L, Samtani S, Ricaurte L, Malapelle U, Russo A, Barrón F, Santoyo N, Rolfo C, Rosell R; ONCOLGroup; CLICaP. Ruiz-Patiño A, et al. Among authors: barron f. Transl Oncol. 2022 Jan;15(1):101276. doi: 10.1016/j.tranon.2021.101276. Epub 2021 Nov 22. Transl Oncol. 2022. PMID: 34823093 Free PMC article.
EGFR Inhibitors Plus Bevacizumab are Superior Than EGFR Inhibitors Alone as First-Line Setting in Advanced NSCLC With EGFR Mutations and BIM Deletion Polymorphisms (BIM-CLICaP).
Cardona AF, Ordóñez-Reyes C, Ruiz-Patiño A, Garcia-Robledo JE, Barron LZ, Recondo G, Rojas L, Corrales L, Martín C, Barrón F, Sotelo C, Rodríguez J, Ricaurte L, Rolfo C, Ávila J, Mayorga D, Archila P, Otero J, Mas L, Bermudez M, Gamez T, Carranza H, Vargas C, Rosell R, Arrieta O. Cardona AF, et al. Among authors: barron f. JCO Precis Oncol. 2021 Nov;5:839-848. doi: 10.1200/PO.20.00404. JCO Precis Oncol. 2021. PMID: 34994616
71 results